Dr. Martens (LON:DOCS) Stock Rating Reaffirmed as “Buy” by Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating reiterated by stock analysts at Berenberg Bank in a report released on Friday, Marketbeat reports. They presently have a GBX 110 target price on the stock. Berenberg Bank’s price objective points to a potential upside of 59.97% from the stock’s previous close.

Dr. Martens Trading Up 1.1%

Shares of DOCS opened at GBX 68.76 on Friday. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. Dr. Martens has a 1 year low of GBX 59.15 and a 1 year high of GBX 97.05. The company has a 50 day simple moving average of GBX 74.25 and a two-hundred day simple moving average of GBX 70.89. The firm has a market cap of £658.16 million, a P/E ratio of 28.65, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.